Surgeons complete first phase of certification training to implant temporary CardioWest Total Artificial Heart

NewsGuard 100/100 Score

On March 4 & 5, the surgical team from the Onassis Cardiac Surgery Center, led by Dr. Petros Sfirakis, Director of the Transplantation Department & Mechanical Support Unit and Dr. Louis Louca, Surgeon/VAD Coordinator, completed the first phase of certification training to implant the SynCardia temporary CardioWest™ Total Artificial Heart. Team members from St. Vincent’s Hospital in Sydney, Australia, also attended the training, including Dr. Phillip Spratt, Head of Cardiopulmonary Transplant and Cardiothoracic Unit, Dr. Paul Jansz, Cardiothoracic and Transplant Surgeon, Mr. Claude Soto, Clinical Perfusionist and Ms. Desiree Robson, Cardiac Mechanical Assist Co-ordinator.

“Heart Transplantation in a Low-Organ-Donation Environment: A Single Center Experience”

“Many people die waiting for a heart transplant in Greece because we have the lowest rate of organ donation in Europe,” said Dr. Sfirakis. “The Total Artificial Heart can save the lives of patients with end-stage biventricular failure and improve their overall health so they are in better condition for their heart transplant.”

Greece has an annual rate of only seven donors per million population. Despite the low number of donor hearts, according to “Heart Transplantation in a Low-Organ-Donation Environment: A Single Center Experience,” (Transplant Proceedings, December 2009), over 13 years (1996-2008), the Onassis Cardiac Surgery Center has achieved post-transplant survival rates of 94% in the first year, 92% at five years and 70% at ten years.

The Onassis Cardiac Surgery Center is the first hospital in Greece and the 51st in the world to complete the first phase of certification training. To become a SynCardia Certified Center, hospitals must apply for and complete a rigorous, four-phase training program, including the first proctored implant by an experienced Total Artificial Heart surgeon.

Ms. Rhonda Walck, Clinical Education Manager for SynCardia’s distributor in Australia and New Zealand, Device Technologies Australia Pty Ltd, also attended the training.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising trend in atrial fibrillation risk over 20 years heightens concern for related heart and stroke complications